Barinthus Biotherapeutics (NASDAQ:BRNS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Barinthus Biotherapeutics Price Performance

Shares of BRNS opened at $0.99 on Friday. The business’s fifty day moving average price is $1.01 and its 200 day moving average price is $1.12. Barinthus Biotherapeutics has a 12-month low of $0.80 and a 12-month high of $4.16. The stock has a market capitalization of $39.83 million, a PE ratio of -0.66 and a beta of -0.80.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $14.97 million during the quarter. As a group, research analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. bought a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th biggest holding. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.